Real‐world retrospective study in elderly patients aged 65 years and older with type 2 diabetes mellitus treated with daily oral semaglutide (SEMA‐elderly)

Aim This real‐world, retrospective cohort study aimed to assess the efficacy, safety and tolerability of oral semaglutide—the first GLP‐1 receptor agonist available in oral form—in patients aged 65 years and older with type 2 diabetes mellitus (T2DM). Materials and Methods The primary endpoint was t...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes, obesity & metabolism obesity & metabolism, 2025-04, Vol.27 (4), p.1805-1814
Main Authors: Fiore, Vincenzo, Carbotta, Giovanni, Barraco, Sonia, Falasca, Paolo, Aricò, Concetta Nadia, Barucca, Alessandra
Format: Article
Language:English
Subjects:
Administration, Oral
Aged
Aged, 80 and over
Blood Glucose - drug effects
Blood Glucose - metabolism
Body Weight - drug effects
Diabetes Mellitus, Type 2 - blood
Diabetes Mellitus, Type 2 - drug therapy
Female
GLP‐1 receptor agonist
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor Agonists
Glucagon-Like Peptides - administration & dosage
Glucagon-Like Peptides - adverse effects
Glucagon-Like Peptides - therapeutic use
glycaemic control
Glycated Hemoglobin - analysis
Glycated Hemoglobin - metabolism
HbA1c
Humans
Hypoglycemic Agents - administration & dosage
Hypoglycemic Agents - adverse effects
Hypoglycemic Agents - therapeutic use
Male
real‐world evidence
Retrospective Studies
semaglutide
Treatment Outcome
type 2 diabetes
Weight Loss - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!